Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD8108 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs AZD 8108 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 17 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 03 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.